ARIAD PHARMACEUTICALS INC 4

Accession 0000884731-16-000075

CIK 0000884731operating

View on SEC.gov Company Profile

Filed

Jun 13, 8:00 PM ET

Accepted

Jun 14, 6:13 PM ET

Size

324.3 KB

Accession

0000884731-16-000075

Insider Transaction Report

Form 4

Period: 2016-06-10

ARIAD PHARMACEUTICALS INCARIA

Radaelli Massimo

Director

Transactions

Exercise/Conversion
Common Stock
2016-06-13$6.38/sh+27,319$174,295→ 132,819 total
Exercise/Conversion
Common Stock
2016-06-13$1.35/sh+2,412$3,256→ 135,231 total
Exercise/Conversion
Common Stock
2016-06-13$6.45/sh+25,000$161,250→ 185,231 total
Exercise/Conversion
Common Stock
2016-06-14$4.91/sh+6,250$30,688→ 111,750 total
Exercise/Conversion
Common Stock
2016-06-10$1.35/sh+22,588$30,494→ 128,088 total
Sale
Common Stock
2016-06-10$8.30/sh−22,588$187,480→ 105,500 total
Sale
Common Stock
2016-06-13$8.25/sh−79,731$657,821→ 105,500 total
Sale
Common Stock
2016-06-14$8.13/sh−6,250$50,834→ 105,500 total
Exercise/Conversion
Stock Option (Right to Buy)
2016-06-13$6.38/sh−27,319$174,159→ 0 total
Exercise: $6.38From: 2011-01-31Exp: 2021-01-31→ Common Stock (27,319 underlying)
Exercise/Conversion
Stock Option (Right to Buy)
2016-06-13$1.35/sh−2,412$3,256→ 0 total
Exercise: $1.35From: 2009-10-10Exp: 2018-10-10→ Common Stock (2,412 underlying)
Exercise/Conversion
Stock Option (Right to Buy)
2016-06-13$7.39/sh−25,000$184,750→ 0 total
Exercise: $7.39From: 2014-03-31Exp: 2024-01-31→ Common Stock (25,000 underlying)
Exercise/Conversion
Stock Option (Right to Buy)
2016-06-13$6.45/sh−25,000$161,250→ 0 total
Exercise: $6.45From: 2015-03-31Exp: 2025-01-31→ Common Stock (25,000 underlying)
Exercise/Conversion
Common Stock
2016-06-13$7.39/sh+25,000$184,750→ 160,231 total
Exercise/Conversion
Stock Option (Right to Buy)
2016-06-10$1.35/sh−22,588$30,494→ 2,412 total
Exercise: $1.35From: 2009-10-10Exp: 2018-10-10→ Common Stock (22,588 underlying)
Exercise/Conversion
Stock Option (Right to Buy)
2016-06-14$4.91/sh−6,250$30,688→ 18,750 total
Exercise: $4.91From: 2016-03-31Exp: 2026-02-01→ Common Stock (6,250 underlying)

Footnotes (9)

[F1]The shares were acquired and sold upon exercise of stock options that would have expired on October 21, 2016 (three months following termination of service as a director), in which event the reporting person would have lost the right to acquire the shares underlying the options.
[F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.25 to $8.2550, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the shares sold at each separate price within the range set forth in this footnote.
[F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.131 to $8.145, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the shares sold at each separate price within the range set forth in this footnote.
[F4]The stock options were granted on 10/10/2008 and vested in three annual installments commencing on 10/10/2009.
[F5]The stock options would have expired on October 21, 2016 (three months following termination of service as a director), in which event the reporting person would have lost the right to acquire the shares underlying the options.
[F6]The stock options were granted on 01/31/2011 and vested as to one-fourth of the options in quarterly installments commencing on March 31, 2011.
[F7]The stock options were granted on 01/31/2014 and vested as to one-fourth of the options in quarterly installments commencing on March 31, 2014.
[F8]The stock options were granted on 01/31/2015 and vested as to one-fourth of the options in quarterly installments commencing on March 31, 2015.
[F9]The stock options were granted on 02/01/2016 and vest as to one-fourth of the options in quarterly installments commencing on March 31, 2016.

Documents

3 files

Issuer

ARIAD PHARMACEUTICALS INC

CIK 0000884731

→

Entity typeoperating

IncorporatedDE

Related Parties

filerCIK 0000884731

Filing Metadata

Form type: 4
Filed: Jun 13, 8:00 PM ET
Accepted: Jun 14, 6:13 PM ET
Size: 324.3 KB

View on SEC.gov